Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute or Early HIV-1 infection~* HIV-1 RNA \> or equal to 500 copies/mL~* Acceptable safety lab results (specified in protocol)~* Negative pregnancy test for females~* Willingness to use contraception (for females of reproductive potential~Exclusion Criteria:~* Prior receipt of investigational HIV-1 vaccine~* Use of immunomodulators other than systemic steroids within 30 days before entry~* Serious medical or psychiatric illness that would interfere with study participation~* Active drug or alcohol use that would interfere with study participation~* Allergy/hypersensitivity to raltegravir~* Pre- or Post-exposure prophylaxis for the exposure that led to HIV-1 acquisition~* Pregnancy or breastfeeding~* History of malignancy (other than localized squamous cell or basal cell cancer of the skin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir + 3-drug anti-HIV therapy (Type: EXPERIMENTAL): None
- 3-drug anti-HIV therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).